Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Northwest Biotherapeutics (NWBO)
:NWBO
Holding NWBO?
Track your performance easily
NWBO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $0.65
Previous CloseN/A
Volume1.45M
Average Volume (3M)2.79M
Market Cap
$351.65M
Enterprise ValueN/A
Total Cash (Recent Filing)$6.19M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,317,990,400
10 Day Avg. Volume2,310,248
30 Day Avg. Volume2,789,018
Standard Deviation0.26
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)216.90
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Northwest Biotherapeutics News
PremiumCompany Announcements
Northwest Biotherapeutics Addresses Market Rumor Concerns
PremiumCompany Announcements
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
PremiumCompany Announcements
Northwest Biotherapeutics Board Veteran Jasinowski Retires
Ownership Overview
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NWBO FAQ
What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was $0.24 and its highest was $0.65 in the past 12 months.
What is Northwest Biotherapeutics’s market cap?
Northwest Biotherapeutics’s market cap is $351.65M.
When is Northwest Biotherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Northwest Biotherapeutics’s earnings last quarter?
Northwest Biotherapeutics released its earnings results on May 16, 2018. The company reported -$0.089 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.089.
Is Northwest Biotherapeutics overvalued?
According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued.
Does Northwest Biotherapeutics pay dividends?
Northwest Biotherapeutics does not currently pay dividends.
What is Northwest Biotherapeutics’s EPS estimate?
Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 1,317,990,400 shares outstanding.
What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
Northwest Biotherapeutics reported an EPS of -$0.089 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Northwest Biotherapeutics?
Currently, no hedge funds are holding shares in NWBO
---
Northwest Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.88%
Trailing 12-Months
Company Description
Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
---
Technical Analysis
Brainstorm Cell Therapeutics
―
China Pharma Holdings
―
Plus Therapeutics
―
Oncolytics Biotech
―
Galectin Therapeutics
―
---